Securities code: 002370 securities abbreviation: Zhejiang Yatai Pharmaceutical Co.Ltd(002370) Announcement No.: 2022-006 bond Code: 128062 bond abbreviation: Asian medicine convertible bond
Zhejiang Yatai Pharmaceutical Co.Ltd(002370)
Announcement on changing the sponsor representative of continuous supervision
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Zhejiang Yatai Pharmaceutical Co.Ltd(002370) (hereinafter referred to as “the company” or ” Zhejiang Yatai Pharmaceutical Co.Ltd(002370) “) recently received the notice on changing the Zhejiang Yatai Pharmaceutical Co.Ltd(002370) sponsor representative from the sponsor Anxin Securities Co., Ltd. (hereinafter referred to as “Anxin securities”). Anxin securities is the sponsor of the company’s public offering of convertible corporate bonds in 2019, and originally designated Mr. Dai Mingchuan Mr. Ye Qingwen is the sponsor representative of the company’s continuous supervision of the project, and the continuous supervision period is until the end of the continuous supervision obligations stipulated by China Securities Regulatory Commission and Shenzhen Stock Exchange.
As Mr. Dai Mingchuan and Mr. Ye Qingwen could not continue to perform relevant continuous supervision due to personal work adjustment, Anxin securities designated Mr. Ji Hongyu and Mr. Chai kechen to take over the continuous supervision of the company’s public offering of convertible corporate bonds and continue to perform relevant duties. After the change of the sponsor representative, the sponsor representatives responsible for the continuous supervision of the company’s public issuance of convertible corporate bonds are Mr. Ji Hongyu and Mr. Chai kechen. The continuous supervision period is until the end of the continuous supervision obligations stipulated by the China Securities Regulatory Commission and Shenzhen Stock Exchange.
See the appendix for the resume of the sponsor representative.
It is hereby announced.
Zhejiang Yatai Pharmaceutical Co.Ltd(002370) board of directors
January 20, 2022
Attachment: resume of sponsor representative
Mr. Ji Hongyu, the sponsor representative, a Chinese certified public accountant, lawyer and asset appraiser, is currently the business director of the investment banking department of Anxin securities. He once served as the sponsor representative of the initial project of Lay-Out Planning Consultants Co.Ltd(300989) (300989) GEM, and participated in Andon Health Co.Ltd(002432) non-public offering of shares and major asset restructuring, Touchstone International Medical Science Co.Ltd(688013) initial public offering and listing on the science and innovation board.
Mr. Chai kechen, the sponsor representative, is now the senior deputy director of life and health industry group of Anxin securities. He has participated in or been responsible for Zhejiang Hisun Pharmaceutical Co.Ltd(600267) non-public offering of shares, Andon Health Co.Ltd(002432) non-public offering of shares and major asset restructuring, Zhejiang Haers Vacuum Containers Co.Ltd(002615) public offering of convertible bonds, Shenzhen Chipscreen Biosciences Co.Ltd(688321) initial public offering of shares and listing on the science and innovation board Touchstone International Medical Science Co.Ltd(688013) has rich investment banking experience in the projects of initial public offering and listing on the science and innovation board, selected layer projects of Shandong digital people Technology Co., Ltd. and selected layer projects of guangmai Technology Co., Ltd.
